Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections

Wolosz,Dominika; Walczak,Agnieszka; Wilczynski,Grzegorz  M.; Szparecki,Grzegorz; Wilczek,Ewa; Gornicka,Barbara

doi:10.3892/ol.2014.2216

Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections

Authors:
- Dominika Wolosz
- Agnieszka Walczak
- Grzegorz M. Wilczynski
- Grzegorz Szparecki
- Ewa Wilczek
- Barbara Gornicka
View Affiliations

Affiliations: Department of Pathomorphology, Medical University of Warsaw, Warsaw, Mazovia 02‑091, Poland, Laboratory of Molecular and Systemic Neuromorphology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Mazovia 02‑093, Poland
Published online on: June 3, 2014 https://doi.org/10.3892/ol.2014.2216
Pages: 785-788

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The deleted in liver cancer (DLC) protein family is composed of proteins that are hypothesized to function predominantly by regulating the activity of the small GTPases. The aim of the present study was to determine the expression and exact localization of DLC1 in hepatocellular carcinoma (HCC) tissue sections. In two types of HCC tissues, typical and fibrolamellar, immunohistochemical and immunofluorescent analysis were performed to assess DLC1 immunoreactivity. Additionally, the DLC1 gene status was determined by the fluorescence in situ hybridization. According to the observations, DLC1 is often lost in cancer cells; however, it can remain within the stromal component of tumor sections. The DLC1 immunoreactivity was particularly noticeable within the capsules surrounding the tumor masses. It was found that the DLC1 gene was deleted in 52% of HCC cases. In addition, the hemizygous deletion was observed to be independent of the HCC subtype. The results indicate that although the loss of DLC1 is a common step during hepatocarcinogenesis, this protein may be present in the tumor microenvironment.

View Figures

View References

1	Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196–2199. 1998.
2	Yuan BZ, Zhou X, Durkin ME, et al: DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 22:445–450. 2003.
3	Lahoz A and Hall A: DLC1: a significant GAP in the cancer genome. Genes Dev. 22:1724–1730. 2008.
4	Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 23:1405–1411. 2004.
5	Wong CM, Yam JW, Ching YP, et al: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 65:8861–8868. 2005.
6	Healy KD, Hodgson L, Kim TY, et al: DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog. 47:326–337. 2008.
7	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687. 2006.
8	Amin R and Mishra L: Liver stem cells and tgf-Beta in hepatic carcinogenesis. Gastrointest Cancer Res. 2(4 Suppl): S27–S30. 2008.
9	Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
10	Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO Classification of Tumours of the Digestive System. 3. 4th edition. IARC; Lyon: 2010
11	Stahl J and Voyvodic F: Biopsy diagnosis of malignant versus benign liver ‘nodules’: new helpful markers. An update Adv Anat Pathol. 7:230–239. 2000.
12	Cremer M, Grasser F, Lanctôt C, et al: Multicolor 3D fluorescence in situ hybridization for imaging interphase chromosomes. Methods Mol Biol. 463:205–239. 2008.
13	Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS and Popescu NC: DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett. 579:1191–1196. 2005.
14	Yang X, Popescu NC and Zimonjic DB: DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res. 71:2916–2925. 2011.
15	Feng M, Huang B, Du Z, Xu X and Chen Z: DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt’s lymphoma cells. Mol Biol Rep. 38:1915–1920. 2011.
16	Zhang T, Zheng J, Liu C and Lu Y: Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int. 82:380–387. 2009.
17	Heering J, Erlmann P and Olayioye MA: Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp Cell Res. 315:2505–2514. 2009.
18	Hankins GR, Sasaki T, Lieu AS, et al: Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery. 63:771–781. 2008.
19	Wong CM, Lee JM, Ching YP, Jin DY and Ng IO: Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63:7646–7651. 2003.
20	Wu SD, Ma YS, Fang Y, Liu LL, Fu D and Shen XZ: Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 38:218–225. 2011.
21	Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. 2006.
22	Amann T, Bataille F, Spruss T, et al: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009.
23	Ramaiah SK and Rittling S: Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 103:4–13. 2008.
24	Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer. 90:1877–1881. 2004.
25	Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 26:6361–6371. 2007.
26	Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME and Popescu NC: DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol. 32:1285–1291. 2008.